Chimeric Therapeutics Ltd

Chimeric Therapeutics (ASX: CHM) has received fast-track designation from the US Food and Drug Administration (FDA) for lead candidate CHM CDH17 to treat gastroenteropancreatic neuroendocrine tumours (GEP-NETs). The FDA based its designation on the drug’s potential to improve outcomes for patients who have progressed beyond at least one prior line of therapy in the advanced […]

Chimeric Therapeutics (ASX: CHM) has received ethics approval for the initiation of a multi-site Phase 1/2 clinical trial of CHM CDH17 in patients with advanced gastrointestinal cancers. CHM CDH17 is a third generation novel CAR T cell therapy aimed at a cancer target associated with poor prognosis and metastasis in the most common gastrointestinal tumours […]

Australian cell therapy specialist Chimeric Therapeutics (ASX:CHM) has achieved another milestone in its efforts to commercialise its CHM 0201 (CORE-NK) “killer cell” technology. Chimeric has received confirmation from the US Patent & Trademark Office (USPTO) that it will allow the issuance of a patent application covering the CHM 0201 technology. CHM 0201 is used to […]

Recent studies have highlighted the significant potential the Australian biotech industry has ahead of it. International research firm KPMG recently forecast Australia could generate over $15 billion in exports to the United States and create 34,000 high-skilled jobs by accelerating US-Australia biotechnology collaboration. Australia’s $1.2b biotech industry currently ranks fifth in the world in terms […]